Cognitive

The cognitive category runs from a cup of coffee to anti-amyloid antibodies, and the evidence varies widely. Many heavily marketed nootropics have limited human data, while caffeine, sleep, and exercise have broader evidence bases. The rankings make that contrast visible.

Strongest consumer-grade evidence

Caffeine has a large evidence base for alertness and vigilance, and caffeine plus L-theanine has been studied for attention with a different subjective-effects profile. Creatine has growing evidence for cognition under stress, sleep deprivation, and low dietary intake. Omega-3 findings vary by population and formulation, while sleep and exercise have broader evidence for day-to-day cognition than most nootropic supplements.

Prescription wakefulness and ADHD agents

Modafinil and armodafinil have strong evidence in narcolepsy and shift-work disorder; in healthy users the benefit is smaller and less consistent, and both are Schedule IV. Amphetamines such as Adderall and Vyvanse have large effects in diagnosed ADHD alongside cardiovascular and dependence risks, with smaller or less consistent cognitive benefits in people without ADHD. Their approved contexts, controlled status, and safety findings are displayed separately.

The speculative corner

Racetams (piracetam and relatives) are widely used but rest on thin, old, or small human studies — they sit at weak evidence tiers here despite their popularity. The Russian peptides Semax and Selank have mostly Russian-language trials with little independent Western replication. Lion’s mane is preliminary. None of this means they do nothing; it means the published human evidence does not yet support a high score, and the rankings say so plainly.

A different audience: the dementia drugs

The anti-amyloid monoclonal antibodies — lecanemab (CLARITY-AD, 2022, ~27% slowing of cognitive decline in early Alzheimer’s) and donanemab — are genuinely disease-modifying, but they are treatments for early Alzheimer’s disease, not enhancers for healthy brains, and they carry ARIA (brain swelling and microbleed) risk. They appear here because they belong to the category, with a use case distinct from everything above.